Literature DB >> 33622919

Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma.

Noritaka Matsuda1, Norihiro Imai2, Teiji Kuzuya3, Kenta Yamamoto1, Takanori Ito1, Yoji Ishizu1, Takashi Honda1, Masatoshi Ishigami1, Mitsuhiro Fujishiro1.   

Abstract

BACKGROUND/AIM: The purpose of this study was to determine changes in the hepatic arteries after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy of transarterial chemoembolization (TACE) as a post-MTA treatment in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: The cases of 33 patients with intermediate HCC treated with MTA and TACE were studied retrospectively. The hepatic arteries, and the safety and efficacy of TACE were evaluated before and after MTA treatment.
RESULTS: Following long-term MTA treatment, the diameters of hepatic arteries decreased significantly, while there was no difference in the diameters of the splenic artery or the portal vein. No significant adverse events were observed due to TACE after MTA; however, the therapeutic effect of TACE was limited after MTA treatment.
CONCLUSION: This study demonstrated that the diameters of hepatic arteries were significantly smaller than those before MTA induction, suggesting ischemic effects and tumor vessel "normalization" by MTA treatment. Although TACE can be performed as a post-MTA treatment without lowering the hepatic reserve or causing serious complications, its therapeutic effect is limited. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Sorafenib; hepatic artery; hepatocellular carcinoma; lenvatinib; transarterial chemoembolization

Year:  2021        PMID: 33622919      PMCID: PMC8045082          DOI: 10.21873/invivo.12367

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  10 in total

1.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

2.  Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment.

Authors:  Teiji Kuzuya; Masatoshi Ishigami; Takanori Ito; Yoji Ishizu; Takashi Honda; Tetsuya Ishikawa; Yoshiki Hirooka; Mitsuhiro Fujishiro
Journal:  Hepatol Res       Date:  2019-05-29       Impact factor: 4.288

3.  Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.

Authors:  Teiji Kuzuya; Masatoshi Ishigami; Takanori Ito; Yoji Ishizu; Takashi Honda; Tetsuya Ishikawa; Mitsuhiro Fujishiro
Journal:  Hepatol Res       Date:  2019-11-12       Impact factor: 4.288

Review 4.  Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.

Authors:  Ann Lii Cheng; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-François Geschwind; Khean L Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Joong-Won Park
Journal:  Liver Int       Date:  2013-11-20       Impact factor: 5.828

5.  Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.

Authors:  Taku Tanaka; Teiji Kuzuya; Masatoshi Ishigami; Takanori Ito; Yoji Ishizu; Takashi Honda; Tetsuya Ishikawa; Mitsuhiro Fujishiro
Journal:  Oncology       Date:  2020-05-20       Impact factor: 2.935

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 7.  Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Authors:  Norihiro Imai; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Yoshiki Hirooka; Hidemi Goto
Journal:  World J Hepatol       Date:  2014-12-27

8.  An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Norihiro Imai; Yoshiaki Katano; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Masatoshi Ishigami; Akihiro Itoh; Yoshiki Hirooka; Hidemi Goto
Journal:  Hepatogastroenterology       Date:  2013 Jul-Aug

9.  Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.

Authors:  Ken Liu; Xiang Zhang; Weiqi Xu; Jinbiao Chen; Jun Yu; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Clin Transl Gastroenterol       Date:  2017-06-15       Impact factor: 4.488

10.  Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study.

Authors:  Ligang Chen; Yifei Zheng; Hongjian Zhang; Heng Pan; Qiusong Liu; Xu Zhou; Wei Wei; Yun Liu; Maochuan Zhen; Jinling Wang; Jianyin Zhou; Yilin Zhao
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

  10 in total
  3 in total

1.  Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.

Authors:  Ruiqing Chen; Lingbing Li; Ye Li; Ke Song; Chenyu Shen; Pengkai Ma; Zhijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment.

Authors:  De-Di Wu; Xiao-Feng He; Chen Tian; Peng Peng; Chuan-Li Chen; Xue-Han Liu; Hua-Jin Pang
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

Review 3.  Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.

Authors:  Liwei Sun; Xuelong Xu; Fanguang Meng; Qian Liu; Hankang Wang; Xiaodong Li; Guijie Li; Feng Chen
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.